A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

NCT05312632 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

201

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: Safinamide Mesilate

Sponsor

Eisai Korea Inc.